Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28560316 | 1.00 | CFTR (0.57) | CFTRPOLBTDP1L3MBTL1LMNA | |
| SCHEMBL3207450 | 0.86 | AGTR2 (0.48) | CFTRPOLBTDP1L3MBTL1LMNA | |
| SCHEMBL37599856 | 0.85 | CFTR (0.59) | CFTRLMNAPKMHTR1AHTR7 | |
| SCHEMBL29409307 | 0.85 | CFTR (0.59) | CFTRLMNAPKMHTR1AHTR7 | |
| SCHEMBL28566774 | 0.85 | CFTR (0.59) | CFTRLMNAPKMHTR1AHTR7 | |
| SCHEMBL4111979 | 0.85 | TDP1 (0.62) | CFTRPOLBTDP1L3MBTL1LMNA | |
| SCHEMBL8495772 | 0.83 | LMNA (0.61) | CFTRPOLBTDP1L3MBTL1LMNA | |
| SCHEMBL4108015 | 0.83 | LMNA (0.50) | CFTRPOLBTDP1L3MBTL1LMNA | |
| SCHEMBL28912058 | 0.83 | NR1D1 (0.61) | CFTRLMNAPKMHTR1AHTR7 | |
| SCHEMBL28560542 | 0.83 | CFTR (0.66) | CFTRTDP1LMNAPKMHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112752837-B | Natural killer cells | 帝国理工学院创新有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12377119-B2 | Natural killer cells | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| US-20220073880-A1 | NATURAL KILLER CELLS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073880-A1 | NATURAL KILLER CELLS | PBK, IKZF3, IKZF1 | CFTR 1048/4885POLB 3281/4885TDP1 4126/4885 |
| US-12377119-B2 | Natural killer cells | PBK, IKZF3, IKZF1 | CFTR 1048/4885POLB 3281/4885TDP1 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.